These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17679929)

  • 1. Male breast cancer during treatment with leuprolide for prostate cancer.
    Yacoub J; Richardson C; Farmer M; Lee WR; Clark PE; Hurt G; Levine EA
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):555-6; discussion 556-7. PubMed ID: 17679929
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast and Prostate Cancer in a BRCA2 Carrier.
    Mahar T; Hicks DG
    Breast J; 2012 Sep; 18(5):511-3. PubMed ID: 22897693
    [No Abstract]   [Full Text] [Related]  

  • 4. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
    Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
    Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 6. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of hormone refractory prostate cancer to lycopene.
    Matlaga BR; Hall MC; Stindt D; Torti FM
    J Urol; 2001 Aug; 166(2):613. PubMed ID: 11458084
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 10. Leuprolide (TAP-144)--a general review.
    Calabrò G; Dell'Acqua L; La Commare P; Parisi C
    J Chemother; 1989 Jul; 1(4 Suppl):1235-6. PubMed ID: 16312847
    [No Abstract]   [Full Text] [Related]  

  • 11. GnRH agonists and prostate cancer.
    Dreicer R
    Am Fam Physician; 1992 Aug; 46(2):374-6. PubMed ID: 1378994
    [No Abstract]   [Full Text] [Related]  

  • 12. Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot?
    Agarwal N; Fletcher D; Ward J
    Clin Cancer Res; 2007 Jul; 13(13):4027. PubMed ID: 17606739
    [No Abstract]   [Full Text] [Related]  

  • 13. The syndrome of inappropriate antidiuretic hormone secretion in a patient with adenocarcinoma of the prostate.
    Gasparini ME; Broderick GA; Narayan P
    J Urol; 1993 Sep; 150(3):978-80. PubMed ID: 8345625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune thyroiditis during leuprolide acetate treatment.
    Eyal O; Rose SR
    J Pediatr; 2004 Mar; 144(3):394-6. PubMed ID: 15001954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
    Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
    Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
    Fackenthal JD; Olopade OI
    Nat Rev Cancer; 2007 Dec; 7(12):937-48. PubMed ID: 18034184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast carcinoma in a male: importance of hormonal receptor expression and possibility of a familial cancer syndrome.
    Forman SB; Tyler WB; Dorion RP; Elston DM
    J Am Acad Dermatol; 2007 Oct; 57(4):731-2. PubMed ID: 17870444
    [No Abstract]   [Full Text] [Related]  

  • 19. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.